Peptide receptor radionuclide therapy (PRRT) using radiolabeled somatostatin receptor (SST) is very effective for treatment of neuroendocrine metastatic tumors. Recent studies indicate that radiolabeled SST antagonists show better tumor targeting during clinical imaging and preclinical therapy, despite little to no internalization in the cancer cells. However, preclinical studies are often limited to activity uptake, with no correlation between the delivered absorbed dose and the biological end-point. This study aims to calculate the absorbed dose to the nucleus for [177Lu]Lu-DOTA-Tyr3,octreotate (177Lu-DOTA-TATE, SST agonist) and [177Lu]Lu-DOTA-JR11 (177Lu- DOTA-JR11, SST antagonist), for comparison with DNA damage induction.
|Title of host publication||Annual Congress of the European Association of Nuclear Medicine October 12 – 16, 2019 Barcelona, Spain|
|Subtitle of host publication||European Journal of Nuclear Medicine and Molecular Imaging volume|
|Number of pages||2|
|State||Published - 16 Oct 2019|